Akili Turns Heel, Goes ‘All In’ On OTC Model For ADHD Digital Therapeutics
“We're taking destiny into our own hands,” says CEO Eddie Martucci.
The Boston, MA-based company says the pivot away from Rx will enable it to pursue a significantly larger market and remove “key friction points” that have prevented patients from accessing its game-based digital ADHD treatment. The company is targeting year-over-year cost savings of $8m-$18m after investments to juice up its direct digital marketing program.
